
GSK: 3-Year Efficacy Data for Arexvy in Older Adults Published in Lancet Respiratory Medicine
A single dose of the AS01E-adjuvanted RSV prefusion F protein-based vaccine (RSVPreF3 OA; Arexvy; GSK) demonstrated 62.9% efficacy against RSV-related lower respiratory tract disease (RSV-LRTD) over 3 consecutive seasons in adults aged 60 years and older, …